

Enter a new dimension of single-cell analysis

Detect RNA and protein simultaneously by flow cytometry
with PrimeFlow™ RNA Assay

Learn more >>

 **affymetrix**
eBioscience



DAP12 Signaling Regulates Plasmacytoid Dendritic Cell Homeostasis and Down-Modulates Their Function during Viral Infection

This information is current as of December 2, 2014.

Hanna Sjölin, Scott H. Robbins, Gilles Bessou, Åsa Hidmark, Elena Tomasello, Maria Johansson, Håkan Hall, Férose Charifi, Gunilla B. Karlsson Hedestam, Christine A. Biron, Klas Kärre, Petter Höglund, Eric Vivier and Marc Dalod

J Immunol 2006; 177:2908-2916; ;
doi: 10.4049/jimmunol.177.5.2908
<http://www.jimmunol.org/content/177/5/2908>

References This article **cites 50 articles**, 26 of which you can access for free at:
<http://www.jimmunol.org/content/177/5/2908.full#ref-list-1>

Subscriptions Information about subscribing to *The Journal of Immunology* is online at:
<http://jimmunol.org/subscriptions>

Permissions Submit copyright permission requests at:
<http://www.aai.org/ji/copyright.html>

Email Alerts Receive free email-alerts when new articles cite this article. Sign up at:
<http://jimmunol.org/cgi/alerts/etoc>

The Journal of Immunology is published twice each month by
The American Association of Immunologists, Inc.,
9650 Rockville Pike, Bethesda, MD 20814-3994.
Copyright © 2006 by The American Association of
Immunologists All rights reserved.
Print ISSN: 0022-1767 Online ISSN: 1550-6606.



DAP12 Signaling Regulates Plasmacytoid Dendritic Cell Homeostasis and Down-Modulates Their Function during Viral Infection¹

Hanna Sjölin,^{2*} Scott H. Robbins,^{2†‡§} Gilles Bessou,^{†‡§} Åsa Hidmark,^{†‡§} Elena Tomasello,^{†‡§} Maria Johansson,^{*} Håkan Hall,^{*} Férose Charifi,^{*‡§} Gunilla B. Karlsson Hedestam,^{*¶} Christine A. Biron,^{||} Klas Kärre,^{*} Petter Höglund,^{*} Eric Vivier,^{†‡§} and Marc Dalod^{3†‡§}

DAP12 is an ITAM-containing adaptor molecule conveying activating properties to surface receptors on many cell types. We show here that DAP12 paradoxically down-modulates plasmacytoid dendritic cell (pDC) cytokine production in vivo during murine CMV (MCMV) infection. Higher levels of IFN- $\alpha\beta$ and IL-12 were detected upon MCMV infection or CpG treatment in DAP12-deficient (DAP12^o) mice as compared with wild-type (WT) mice. This resulted from altered homeostasis and enhanced responsiveness of pDCs in DAP12^o animals. Increased numbers of pDCs were observed in the periphery of both naive and MCMV-infected DAP12^o mice. A higher proportion of pDCs was activated in infected DAP12^o mice, as demonstrated by intracellular staining using an optimized protocol for simultaneous detection of IFN- α and IFN- β . The homeostasis of WT and DAP12^o pDCs did not differ in mixed bone marrow chimeric mice. In addition, a similar efficiency of pDC differentiation was observed in vitro in Fms-like tyrosine kinase receptor 3 ligand cultures of WT and DAP12^o bone marrow cells. This suggests that DAP12 signaling effects on pDC homeostasis are indirect. In contrast, in response to CpG, DAP12-mediated effects on both IL-12 and IFN- $\alpha\beta$ production were intrinsic to the pDCs. However, in response to MCMV, only IL-12 but not IFN- $\alpha\beta$ production was affected by pDC-intrinsic DAP12 signaling. Thus, DAP12 signaling in pDCs can mediate different regulatory effects on their functions, depending on the mechanisms of pDC activation. The potential implications of the regulation of pDC functions by DAP12 for promoting health over disease are discussed. *The Journal of Immunology*, 2006, 177: 2908–2916.

Plasmacytoid dendritic cells (pDCs)⁴ have been shown to exert pleiotropic activating or inhibitory roles in the regulation of immune responses (1). pDCs play a critical role in early antiviral defense as the main source of IFN- $\alpha\beta$ and eventual coproducers of other cytokines such as IL-12 (1). IFNs- $\alpha\beta$ are

critical for host resistance against viral infection, both through direct antiviral effects and through promotion of dendritic cell (DC) (2–4) and CD8 T cell (5) responses. IFN- $\alpha\beta$ can also exert many other immunoregulatory functions, either activating or inhibitory (6–13), and excessive production of IFN- $\alpha\beta$ or other innate cytokines can be detrimental to the host under various pathological conditions (1, 12, 14). For example, the excessive production of IFN- $\alpha\beta$ by pDCs has been implicated in the development of autoimmune disease such as lupus erythematosus (10, 11) or psoriasis (9). In contrast, pDCs have been shown to participate to the induction of T cell tolerance (15–18) and to confer protection against allergic responses (19). Thus, pathways must be in place that differentially regulate pDC innate cytokine production under various conditions to promote health over disease.

The molecular pathways promoting pDC recognition of and responses to viral components have been partly identified. TLR-7, -8, and -9 bind viral single-stranded RNA or CpG DNA sequences in endosomal compartments where they signal through the MyD88 adaptor molecule for induction of IFN- $\alpha\beta$ and IL-12 production (1). However, much less is known regarding the negative regulation of pDC functions in vivo. In vitro studies have demonstrated that human pDCs can be inhibited by engagement of the blood DC Ag 2 lectin receptor (20) or the Nkp44 receptor (21). Furthermore, a nondeleting pDC-specific Ab has been shown to inhibit CpG-induced IFN- $\alpha\beta$ production in vivo in mice (22). Collectively, these data suggest that pDC functions are tightly regulated by the integration of activation signals derived from TLRs and modulatory signals delivered by other cell surface receptors. However, it is not documented whether and how cell surface receptors expressed on pDCs limit their production of cytokines during viral infection in vivo.

*Microbiology and Tumor Biology Center and Strategic Research Center for Studies of Integrated Recognition in the Immune System, Karolinska Institute, Stockholm, Sweden; [†]Centre d'Immunologie de Marseille-Luminy, Université de la Méditerranée, Case 906, Marseille, France; [‡]Institut National de la Santé et de la Recherche Médicale, Unité 631, Marseille, France; [§]Centre National de la Recherche Scientifique, Unité Mixte de Recherche 6102, Marseille, France; [¶]Section of Vaccine Research, Swedish Institute for Infectious Disease Control, Solna, Sweden; and ^{||}Department of Molecular Microbiology and Immunology, Division of Biology and Medicine, Brown University, Providence, RI 02912

Received for publication February 27, 2006. Accepted for publication June 16, 2006.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ This work was supported in part by an Actions Thématiques Initiatives sur Programmes grant from Centre National de la Recherche Scientifique (CNRS) (to M.D.), a grant from Association pour la Recherche sur le Cancer (to M.D.), and support from the Swedish Foundation for Strategic Research and the Swedish Research Council (to K.K. and H.S.). S.H.R. was supported by CNRS, Fondation pour la Recherche Médicale, the Philippe Foundation, and the city of Marseille. Centre d'Immunologie de Marseille-Luminy is supported by institutional grants from Institut National de la Santé et de la Recherche Médicale, CNRS, and Université de la Méditerranée.

² H.S. and S.H.R. contributed equally to this work.

³ Address correspondence and reprint requests to Dr. Marc Dalod, Centre d'Immunologie de Marseille-Luminy, Parc Scientifique de Luminy, Case 906, F-13288 Marseille Cedex 09, France. E-mail address: dalod@ciml.univ-mrs.fr

⁴ Abbreviations used in this paper: pDC, plasmacytoid dendritic cell; DC, dendritic cell; cDC, conventional DC; MCMV, murine cytomegalovirus; DAP12^o, DAP12-deficient; BM, bone marrow; BMC, bone marrow chimeric; FLT3-L, Fms-like tyrosine kinase receptor 3 ligand; ODN, oligodeoxynucleotide; PDCA-1, plasmacytoid DC Ag 1; WT, wild type.

Some receptors on DCs require association with the KARAP/DAP12/TYROBP adaptor molecule for cell surface expression and signal transduction. DAP12 carries an ITAM and mediates a multiplicity of functions in a variety of cell types (23–25). DAP12 and the associated receptor triggering receptor expressed on myeloid cells 1 amplify macrophage inflammatory responses and increase mortality in mice undergoing LPS-induced shock or septic peritonitis upon caecal ligation and puncture (26, 27). In contrast, DAP12 has also been reported to down-modulate macrophage inflammatory responses to TLR or CD16 triggering and to limit susceptibility to another model of endotoxic shock induced by the combination of LPS and D-galactosamine (28). Thus, the role of DAP12 in regulating inflammation may depend on the cell type, the stimuli, or the disease studied. Interestingly, NKp44 signals through DAP12, suggesting a possible involvement of this signaling adaptor in the inhibition of IFN- $\alpha\beta$ production by tonsil pDCs upon engagement of the receptor (21). Recently, DAP12 has been shown to inhibit IFN- $\alpha\beta$ production in response to CpG stimulation *in vitro* and *in vivo* in the mouse (29). Cross-linking of the DAP12 associated receptor Siglec-H on pDCs leads to inhibition of CpG induced IFN- $\alpha\beta$ production (29). However, it is not known whether DAP12 functions regulate pDC production of other cytokines induced by TLR-9 triggering, whether DAP12 regulates DC responses *in vivo* during natural infections, or what the respective roles of the intrinsic vs extrinsic effects of DAP12 for the regulation of pDC functions are.

Defense against murine CMV (MCMV), an established model for studying human CMV infection, is heavily dependent on DC and NK cell responses (30). Early after MCMV infection, IFN- $\alpha\beta$ is mainly produced by pDCs, whereas IL-12 can be produced by several DC subsets (3, 31, 32). TLR-9-derived or other MyD88-dependent signals are important for optimal activation of pDCs and conventional DCs (cDCs) in response to MCMV (32–34). DAP12 signaling is essential for triggering anti-MCMV NK cell effector functions upon engagement of the Ly49H activating receptor by a viral ligand expressed on infected cells (30, 35). However, whether DAP12 signaling modulates pDC responses during viral infection is unknown.

Here, we provide the first evidence of a role for DAP12 in the modulation of pDC activation during a viral infection *in vivo*. We identify a role for DAP12 in the differential regulation of IL-12 and IFN- $\alpha\beta$ production by pDCs. Moreover, by comparing viral infection to CpG treatment, we show that the outcome of DAP12 signaling on pDC cytokine production must depend on the combination of pattern recognition or cytokine receptors that are engaged for pDC activation.

Materials and Methods

Mice

C57BL/6, B10.D2, B6-DAP12.KI, B6-DAP12.KO, and B10.D2-DAP12.KI mice were bred in pathogen-free breeding facilities at Centre d'Immunologie de Marseille-Luminy (Marseille, France) and at the Microbiology and Tumorbiology Center, Karolinska Institute (Stockholm, Sweden). Bone marrow chimeric mice (BMC) were generated by irradiation of CD45.1⁺ C57BL/6 (B6.SJL-*Ptprc*³) *Pep3*^b/BoyCr1 (Charles River Laboratories) at 1,000 rad and reconstitution by *i.v.* injection of bone marrow (BM) cells, either CD45.1 wild-type (WT) and CD45.2 WT BM cells at a 1:1 ratio or CD45.1 WT and CD45.2 DAP12-deficient (DAP12⁰) BM cells at a 1:1 ratio. Experiments on BMC mice were performed 12–13 wk after generation. Experiments were conducted in accordance with institutional guidelines for animal care and use. Protocols have been approved by the French Provence ethical committee (no. 04/2005), the U.S. Office of Laboratory Animal Welfare (assurance no. A5665-01), and the Committee for Animal Ethics in Stockholm, Sweden.

In vivo treatment protocols

Infections of MCMV were initiated at day 0 by *i.p.* delivery or 1×10^5 PFU of Smith strain MCMV salivary gland extracts (31). Infected mice were harvested at the peak of innate cytokine production by pDCs, which occurs at day 1.5 postinfection (31). CpG oligodeoxynucleotide (ODN) 2216 and control ODN 2243 were synthesized by Sigma-Aldrich and mixed with 1,2-dioleoyloxy-3-(trimethylammonium)propane reagent as described (4), and 10 μ g of the ODN was injected *i.v.* CpG-treated mice were harvested at 3 h postinjection for cytokine stainings in spleen pDCs, at a time where serum cytokine titers are close to their peak, as described (4). No cytokine production was detected in mice injected with control ODN 2243 (not shown).

Lymphocyte isolation, cell surface, and intracellular staining

Lymphocytes were isolated from spleens, livers, and lymph nodes as previously described (31, 35). Abs against NK1.1, CD8 α , TCR- β , CD11c, IL-12p40/p70, CD45.1, and CD45.2 as well as isotype controls and streptavidin were purchased from BD Pharmingen. The plasmacytoid DC Ag 1 (PDCA-1) mAb was purchased from Miltenyi Biotec, biotinylated goat anti-rat IgG was from Jackson ImmunoResearch Laboratories, and purified rat anti-mouse IFN- α (clone F18 or clone RMMA-1) and anti-IFN- β (clone RMMB-1) were from Tebu-bio. mAb 120G8 (36) was provided by Schering-Plough and conjugated to Alexa 488 using a labeling kit from Invitrogen Life Sciences. Protocols for the staining of cell surface markers and intracellular staining of cytokines were adapted (4, 31). No staining for IFN- $\alpha\beta$ was observed in uninfected animals. In infected animals, the background staining with an isotype control Ab was <0.1% (not shown). Depending on the experiments, 2.5×10^5 to 2×10^6 events were collected on a FACSCalibur or FACSCanto.

Cell sorting, RNA isolation, and RT-PCR

NK cells (NK1.1⁺TCR β ⁻), pDCs (CD11c^{intermediate}120G8⁺), CD8 α ⁺cDCs (CD11c^{high}120G8⁻CD8⁺), and CD8 α ⁻cDCs (CD11c^{high}120G8⁻CD8 α ⁻) were enriched from the spleen of C57BL/6 mice by positive selection using magnetic beads (anti-DX5 or a mix of anti-CD11c and anti-PDCA1, respectively, all from Miltenyi Biotec) and further purified to >98% on a FACSAria flow cytometer. RNA were isolated using the RNeasy micro kit (Qiagen) with DNase treatment to remove any potential contamination by genomic material in accordance with the instructions of the manufacturer. The levels of expression of different genes were evaluated by RT-PCR after 28, 30, 32, 35, or 40 amplification cycles. The data shown for each primer pair correspond to the cycle number at which it could be detected but was not yet at saturation. The primer pairs in parentheses were used for the following target genes: *DAP12* (forward, 5'-GCTCTGGAGCCCTCTGGTGC-3'; reverse, 5'-CTCAGTCTCAGCAATGTGTTG-3'; product size: 261 bp on cDNA, no genomic product); *CD200R4* (forward, 5'-TCCAGATGAGGGACTAC-3'; reverse, 5'-GGCACATTCAAACACAATCG-3'; product size: 636 bp on cDNA, >5000 bp on genomic); *Ly49H* (forward, 5'-AGGCATCCATTCTTCTACC-3'; reverse, 5'-ACTCTTGGTTTCACTGTCCC-3'; product size: 482 bp on cDNA, >4000 bp on genomic); *Mair-II* (forward, 5'-TTCGAGCCTTGAGAGTGGTAG-3'; reverse, 5'-GCTCAGGAACAGGAACTTCC-3'; product size: 178 bp on cDNA, >1300 bp on genomic); *NKG2D* (forward, 5'-AACAAGGAAGTCCCAGTTTCC-3'; reverse, 5'-TTACACAGCCCTTTTCATGCA-3'; product size: 402 bp on cDNA, >3000 bp on genomic); *SIRP- β* (forward, 5'-TGTGAAGTCCAGAGAGGACCATGAGCC-3'; reverse, 5'-TAGGTTCCAACACCACCTGACTGTGCTGG-3'; product size: 299 bp on cDNA, >5000 bp on genomic); *actin* (forward, 5'-CATCCATCATGAAGTGTGACG-3'; reverse, 5'-CATACTCCTGCTTGCTGATCC-3'; product size: 247 bp on cDNA, 247 plus 370 bp on genomic).

Cytokine titrations

IFN- $\alpha\beta$ bioassay was performed as described (37). IFN- α , IFN- β , and IL-12p40 or IL-12p70 ELISAs were performed using commercial kits distributed by PBL Laboratories and R&D Systems, respectively.

Fms-like tyrosine kinase receptor 3 ligand (*FLT3-L*) bone marrow cell cultures

BM-DC were derived from bone marrow cells in cultures treated with murine recombinant FLT-3L (25 ng/ml; R&D Systems) as previously described (38).




FIGURE 1. RT-PCR analysis of the expression of DAP12 and selected associated receptors in pDC and other leukocytes. Leukocyte populations were sorted to >98% purity from the spleen of C57BL/6 mice, and serial dilutions of the cDNA generated from these cells were three to five amplified by PCR. Data are representative of three to five PCRs two to three using two to three sets of independently sorted cells.

Statistical analyses

Statistical analyses were performed using Student's two-tailed *t* tests. Unless otherwise indicated, means \pm SD are shown.

Results

DAP12 and several associated receptors are expressed in pDCs at the mRNA level

Various cell types like DCs, monocytes, and NK cells express DAP12 and associated receptors (23). It has recently been shown that the lectin Siglec-H is specifically expressed on pDCs and requires DAP12 for cell surface expression (29). We studied DAP12 expression in purified NK cells and DC subsets by RT-PCR and found high levels of mRNA encoding DAP12 in all cell populations (Fig. 1). Importantly, several known DAP12-associated receptors in addition to Siglec-H were expressed in pDCs at mRNA levels comparable or higher to those observed in cDCs or in NK cells (i.e., NKG2D, CD200R4, and MAIR-II) (Fig. 1 and Table I). Thus, DAP12 and a variety of associated receptors are expressed in pDCs and could therefore directly take part in regulating pDC functions.

Increased cytokine production in DAP12^o mice in response to MCMV infection or CpG treatment

To examine the impact of DAP12 functions on pDC antiviral responses, we measured titers of IFN- $\alpha\beta$ in the sera and spleen homogenates of day 1.5 MCMV-infected DAP12^o or WT animals by bioassay and ELISA. We observed a significant increase in

IFN- $\alpha\beta$ production both in the serum (Fig. 2) and spleen homogenate (not shown) of DAP12^o mice compared with WT controls. We next measured IFN- $\alpha\beta$ production in animals injected with a synthetic TLR-9 agonist, CpG ODN 2216. Again, there was a significant increase in production of IFN- $\alpha\beta$ in the serum of DAP12^o

Table I. Expression of the genes encoding DAP12 and selected associated receptors in DC subsets and NK cells as assessed by semiquantitative RT-PCR^a

Gene	Cell Type			
	pDC	CD11b DC	CD8 α DC	NK
<i>dap12</i>	+++	++	++	+++
<i>cd200r3</i>	—	—	—	—
<i>cd200r4</i>	+	+	+	+++
<i>ly49h</i>	—	—	—	+++
<i>mairll</i>	+++	+++	+++	+
<i>mdl-1</i>	—	—	—	—
<i>nkg2d</i>	++	++	++	+++
<i>pirlb</i>	+	+++	+	—
<i>siglec-h</i>	+++	—	—	—
<i>sirp-β</i>	—	+++	—	—
<i>trem1</i>	—	—	—	—
<i>trem2</i>	—	—	—	—
<i>trem3</i>	—	++	—	—

^a +, ++, and +++ indicate increasing levels of expression; — indicates undetectable.




FIGURE 2. Increased serum levels of IFN- $\alpha\beta$ in DAP12 $^{\circ}$ mice in response to MCMV infection or CpG injection. Serum was isolated from WT and DAP12 $^{\circ}$ mice that were uninfected or day 1.5 (d1.5) MCMV infected (left panel) and from mice that had been treated with control ODN or CpG 2216 for 3 h (right panel). IFN- $\alpha\beta$ levels as determined by bioassay are shown. Similar results were obtained by using IFN- α and IFN- β ELISA (not shown). Results are expressed as mean \pm SD of three mice per group. One experiment representative of three is shown. *, $p \leq 0.01$; **, $p \leq 0.05$.

mice (Fig. 2). Similarly, increased levels of IL-12p40 were observed in spleen homogenates of CpG-treated or MCMV-infected DAP12 $^{\circ}$ animals as compared with their WT counterparts (not shown). These data show that DAP12 signaling can lead to the down-modulation of IFN- $\alpha\beta$ and IL-12 production by pDCs in response to MCMV infection or CpG treatment in vivo.

Increased pDC numbers in the periphery of DAP12 $^{\circ}$ mice

Because the tissue distribution of cells bearing generic markers of DCs such as CD11c or MHC class II is affected in DAP12 $^{\circ}$ mice (39), we investigated whether the increased production of IFN- $\alpha\beta$ observed in DAP12 $^{\circ}$ animals could be attributed to an alteration of pDC homeostasis. We therefore measured DC subset frequency and numbers in multiple organs of DAP12 $^{\circ}$ and WT animals. There was a significant increase in the proportions of pDCs to total splenocytes in DAP12 $^{\circ}$ mice (Fig. 3, A and B). In contrast, the percentages of CD8 α cDCs and NK cells were unchanged, whereas the frequency of CD11b cDCs was slightly but not significantly decreased. Overall, the percentages and absolute numbers of pDCs were significantly increased in spleen, lymph nodes, and livers of DAP12 $^{\circ}$ mice (Table II). Viral infection (Fig. 3, C and D) and CpG stimulation (data not shown), preserved higher numbers of pDCs in DAP12 $^{\circ}$ mice as compared with WT controls. pDC accumulation in the periphery of DAP12 $^{\circ}$ mice resulted neither from increased differentiation of pDCs in BM nor from longer half-life in the periphery. BM from WT and DAP12 $^{\circ}$ animals had the same frequency and numbers of pDCs (Fig. 4, A and B), and BM cells from both strains showed similar potential for pDC differentiation in vitro upon FLT3-L stimulation (Fig. 4, C and D). No major differences were observed in the half-life of WT vs DAP12 $^{\circ}$ pDC in the periphery as measured by the kinetics of BrdU incorporation in vivo (data not shown).

To determine whether DAP12 regulation of pDC homeostasis was at least in part cell intrinsic, we generated mixed BMC mice from lethally irradiated CD45.1 $^{+}$ WT recipients reconstituted with BM of CD45.2 $^{+}$ DAP12 $^{\circ}$ or CD45.2 $^{+}$ WT donors mixed in a 1:1 ratio with the BM of WT CD45.1 $^{+}$ donors. We analyzed the reconstitution of WT and DAP12 $^{\circ}$ pDCs, cDCs, and NK cells in the spleens of those animals. There was no increase in the proportion of CD45.2 $^{+}$ over CD45.1 $^{+}$ pDCs in the DAP12 $^{\circ}$ /WT as compared




FIGURE 3. Increased numbers of pDCs in the spleen of DAP12 $^{\circ}$ mice in naive mice and at day 1.5 (d1.5) post-MCMV infection. Splenic leukocytes were isolated from naive WT and DAP12 $^{\circ}$ mice on day 1.5 post-infection and analyzed for pDC, CD11b DC, CD8 α DC, and NK cell frequencies. A, pDC (PDCA-1 $^{+}$ CD11c intermediate), CD11b DC (PDCA-1 $^{-}$ CD11c high CD8 α^{-}), CD8 α DC (PDCA-1 $^{-}$ CD11c high CD8 α^{+}), and NK cell (TCR β^{-} NK1.1 $^{+}$) frequency is shown for one representative WT and one representative DAP12 $^{\circ}$ animal from groups of three mice. Numbers in dot plots represent the percentage of gated cell population within total splenocytes. T and NK lineage positive cells (TCR β^{+} or NK1.1 $^{+}$) were electronically excluded from the DC plots. B, Graphic representation of the relative frequency of the three splenic DC subsets in comparison to one another for one representative WT and DAP12 $^{\circ}$ animal. C, cDC (120G8 $^{-}$ CD11c high) and pDC (120G8 $^{+}$ CD11c int) frequency is shown for one representative d1.5 MCMV-infected WT animal and DAP12 $^{\circ}$ animal from groups of three mice. Numbers in dot plots represent the percentage of gated cell population within total splenocytes. D, Total numbers of splenic cDCs and pDCs from naive and d1.5 MCMV-infected WT and DAP12 $^{\circ}$ mice. Results are expressed as mean \pm SD of three mice per group. One experiment representative of three is shown in each panel. *, $p \leq 0.01$; **, $p \leq 0.05$.

with the WT/WT BMC. Indeed, similar percentages of CD45.2 $^{+}$ cells, whether WT or DAP12 $^{\circ}$, were observed in the three cell types studied: pDCs, cDCs, and NK cells (Fig. 5). Altogether, these results show that DAP12 regulation of pDC homeostasis is not cell intrinsic but must occur as a consequence of DAP12 modulation of the functions of other cells. Irrespective of the nature of these cells, which remains to be identified, the accumulation of

Table II. Frequencies of pDCs and NK cells in different organs of WT or DAP12° mice^a

Strain	Spleen			Lymph Node			Liver		
	Total ($\times 10^{-8}$)	pDC ($\times 10^{-6}$)	NK ($\times 10^{-6}$)	Total ($\times 10^{-6}$)	pDC ($\times 10^{-3}$)	NK ($\times 10^{-4}$)	Total ($\times 10^{-6}$)	pDC ($\times 10^{-5}$)	NK ($\times 10^{-5}$)
B10.D2	1.46 ± 0.04	1.1 ± 0.1	5.1 ± 0.6	2.9 ± 0.2	3.5 ± 0.7	3.3 ± 0.6	5.6 ± 0.3	0.8 ± 0.2	6.7 ± 0.1
B10.DAP12.KI	1.48 ± 0.03	3.0 ± 0.3	5.7 ± 0.1	3.1 ± 0.3	10.2 ± 1.1	2.7 ± 0.2	5.9 ± 0.3	1.8 ± 0.1	7.2 ± 1.0
C57BL/6	1.44 ± 0.06	0.6 ± 0.1	2.7 ± 0.4	3.0 ± 0.1	1.8 ± 0.0	1.2 ± 0.0	6.4 ± 0.3	0.8 ± 0.1	5.7 ± 1.0
B6.DAP12.KI	1.43 ± 0.07	1.8 ± 0.4	3.1 ± 1.1	3.1 ± 0.2	7.5 ± 0.4	1.5 ± 0.3	6.7 ± 0.2	1.5 ± 0.1	6.4 ± 1.2
C57BL/6	1.40 ± 0.03	0.8 ± 0.2	6.8 ± 1.1	3.1 ± 0.2	10.6 ± 0.1	3.0 ± 0.0	6.1 ± 0.7	0.8 ± 0.1	3.1 ± 1.0
B6.DAP12.KO	1.44 ± 0.02	1.9 ± 0.1	6.6 ± 1.3	3.5 ± 1.5	21.0 ± 1.1	2.2 ± 0.5	6.3 ± 0.3	1.4 ± 0.0	3.9 ± 0.7

^a Bold, $p \leq 0.01$.

pDCs in the periphery of DAP12° mice was true for two different genetic backgrounds, C57BL/6 and B10.D2, and for two different models of genetic inactivation (Table II), mice expressing a mutated DAP12 molecule devoid of signaling function (B6.DAP12.KI) (39) and mice knocked out for the *dap12* gene (B6.DAP12.KO) (40). Thus, DAP12 functions regulate pDC homeostasis by limiting pDC numbers in the periphery. The higher numbers of pDCs in DAP12° mice could in part explain the increased production of IFN- $\alpha\beta$ in these animals.

Increased frequency of cytokine-producing pDCs in DAP12° mice upon MCMV infection or CpG injection

In addition to increased pDC numbers, enhanced reactivity of pDCs for response to viral infection could also contribute to the overall increase in cytokine production observed in DAP12° mice. To address this issue, we established an optimized intracellular staining protocol for simultaneous detection of both IFN- α and IFN- β . We measured IFN- $\alpha\beta$ and IL-12 production ex vivo in individual cells of infected animals by intracellular staining. There was a clear staining for IFN- $\alpha\beta$ in pDCs (Fig. 6A) without any detectable signals in cDCs from the same sample (not shown). These data confirm our previous demonstrations that pDCs are the major producers of these cytokines early after MCMV infection (3, 31, 32). The proportions of IFN- $\alpha\beta$ - or IL-12-expressing pDCs were significantly higher in the DAP12° mice as compared with WT animals (Fig. 6, A and B). These data were further confirmed by measuring ex vivo cytokine production in conditioned medium from pDCs purified from MCMV-infected mice. These experiments showed a >3-fold increase in the production of IL-12p70 and IFN- $\alpha\beta$ by the pDCs from DAP12° mice over that from the WT animals (5335 vs 1420 pg/ml and 233 vs 67 U/ml, respectively, for one representative experiment of two). Increases in the percentages of pDC producing IFN- $\alpha\beta$ or IL-12 were also observed in DAP12° mice in response to CpG injection in vivo (Fig. 6, C and D).

Contrasting role of DAP12 signaling in pDCs for regulation of IL-12 vs IFN- $\alpha\beta$ production in response to MCMV infection

To determine whether DAP12 regulation of pDC cytokine production in vivo was at least in part cell intrinsic, we generated mixed BMC mice from DAP12° and WT donors as described above. We then analyzed, in each BMC mouse, pDC cytokine production separately for the two types of donor cells as identified by CD45.1 or CD45.2 allotypic markers. CpG stimulation of the mixed BMC mice gave rise to a strong and significant increase in the percentages of both IFN- $\alpha\beta$ and IL-12 producing cells within the DAP12° pDCs as compared with the WT pDCs (Fig. 7). Thus, DAP12 is

functional in pDCs and limits their production of IL-12 and IFN- $\alpha\beta$ in vivo in response to TLR-9 triggering.

NK cell-mediated control of viral replication is heavily reduced in the DAP12° mice (35) because of the loss of NK cell ability to kill infected cells through Ly49H engagement and subsequent DAP12-dependent triggering of cytotoxic effector functions. Thus, the increased cytokine production in DAP12° animals could have resulted at least in part from increased amounts of viral products able to stimulate pDCs. For the purpose of comparing cytokine production by WT vs DAP12° pDCs in response to viral infection within the exact same pathophysiological context, including the efficiency of NK cell control of viral replication, we next infected mixed BMC mice with MCMV (Fig. 7). In MCMV-infected mixed BMC mice a higher proportion of DAP12° pDCs produced IL-12 as compared with their WT counterparts, consistent with what was observed in response to CpG treatment. However, within the same mixed BMC mouse infected with MCMV there were no differences in the percentage of IFN- $\alpha\beta$ -producing DAP12° pDCs as compared with the WT pDCs. Thus, intrinsic DAP12 signaling in pDCs specifically inhibited production of IL-12, but not IFN- $\alpha\beta$, during MCMV infection.

Collectively, these data demonstrated that DAP12 is functional in pDCs and differentially limits their production of IL-12 vs IFN- $\alpha\beta$ in vivo in response to infectious or noninfectious challenges.

Discussion

We demonstrate here for the first time that DAP12 signaling regulates pDC homeostasis and down-modulates pDC cytokine production in response to viral infection in vivo. Compared with WT controls, DAP12° mice produced more IL-12 and IFN- $\alpha\beta$ in response to viral infection or to CpG stimulation. This result was due both to increased total numbers of pDCs and to higher frequencies of cytokine-producing pDCs in DAP12° animals. The development of WT and DAP12° pDCs did not differ in mixed BMC mice or in BM cell cultures. This finding shows that DAP12 regulation of pDC homeostasis is not cell intrinsic. Thus, it must occur as a consequence of DAP12 modulation of the functions of other cells. The outcome of intrinsic DAP12 signaling in pDCs for cytokine production upon CpG challenge or viral infection was evaluated in mixed BMC mice. DAP12 signaling in pDCs reduced both IL-12 and IFN- $\alpha\beta$ production in response to CpG. In contrast, MCMV infection was able to override the intrinsic inhibitory signals mediated by DAP12 in pDCs specifically for IFN- $\alpha\beta$ production, but not for that of IL-12.

Why were IFN- $\alpha\beta$ serum levels elevated in the DAP12° mice after MCMV infection, when the experiments based on mixed




FIGURE 4. Normal differentiation of DAP12° pDCs from BM cells. BM cells were isolated from naive WT and DAP12° mice and analyzed for pDC and NK cell frequencies directly ex vivo or for pDC differentiation in vitro upon FLT3-L stimulation. *A*, pDC (PDCA-1⁺ CD11c^{intermediate}) and NK cell (TCRβ⁻NK1.1⁺) frequency is shown for one representative WT and DAP12° animal from groups of three mice. Numbers in dot plots represent percentage of gated cell population within total BM cells. T and NK lineage positive cells (TCRβ⁺ or NK1.1⁺) were electronically excluded from the DC plots. *B*, Total numbers of BM pDCs and NK cells from WT and DAP12° mice. Results are expressed as mean ± SD of three mice per group. One experiment representative of three for is shown. *C*, cDC (120G8⁻ CD11c^{high}) frequency and pDC (120G8⁺ CD11c^{intermediate}) frequency are shown for one representative FLT3-L culture from WT and DAP12° BM cells from groups of three mice. Numbers in dot plots represent percentage of gated cell population within total cells in culture. *D*, Total numbers of pDCs and cDCs in FLT3-L culture wells from WT and DAP12° BM cells. Results are expressed as mean ± SD of three mice per group. One experiment representative of three is shown for each panel.





FIGURE 5. Normal differentiation of DAP12° pDCs in mixed BMC mice. Frequency of WT or DAP12° CD45.2⁺ pDCs, cDCs, or NK cells from mixed BMC mice. WT-CD45.1⁺ recipient animals were lethally irradiated and reconstituted with WT-CD45.1⁺/WT-CD45.2⁺ or WT-CD45.1⁺/DAP12°-CD45.2⁺ BM cell mixtures. For each mouse, a gate was set on pDCs (CD11c^{intermediate}PDCA-1⁺), another on cDCs (CD11c^{high}PDCA-1⁻), and a third on NK cells (NK1.1⁺TCRβ⁻). The frequency of CD45.2⁺ cells in each gate was then measured. Results are expressed as mean ± SD of three mice per group for each pDC population. One experiment representative of two is shown.

BMC mice demonstrated that intrinsic DAP12 signaling in pDCs did not modulate significantly IFN-αβ production? Our interpretation is that in DAP12° animals the DAP12-mediated regulation of pDC IFN-αβ production upon MCMV infection is indirect, occurring through altered functions of other cell types, probably NK cells. Indeed, antiviral NK cell responses are decreased in DAP12° animals because of the loss of triggering of cytotoxic effector functions upon the recognition of infected cells by the DAP12-associated receptor Ly49H (30, 35). This deficit in NK cell functions leads primarily to increased viral replication, which could in turn enhance triggering of pattern recognition receptors on pDCs and thus increase IFN-αβ production.

During the course of this study, DAP12 deficiency was shown to increase IFN-αβ titers in serum after CpG challenge in mice and in pDC cultures in vitro (29). Our data confirm and extend this finding. Together with our studies during MCMV infection, the data support a role of DAP12 signaling in pDCs for regulation of their responses to TLR triggering. Intracellular signaling cascades originating from DAP12 could interfere with the TLR signaling pathways in different ways. Lack of endogenous DAP12 signaling during pDC development or maturation might alter expression levels of molecules involved in TLR signaling and prime pDCs for enhanced reactivity to pathogen-associated molecular patterns. However, because it was recently shown that triggering of the DAP12-associated receptor Siglec-H on mature WT pDCs limits IFN-αβ production upon CpG challenge (22, 29), there clearly exists direct cross-talk between TLR-mediated and DAP12-mediated signaling pathways in mature pDCs. The cross-linking of DAP12 associated receptors may directly interplay with molecules otherwise involved in TLR signaling pathways, either in a competition for shared molecules as was recently suggested (29) or by directly recruiting inhibitory intracellular factors that dampen TLR signaling or expression of IFN-αβ genes (41).

Why was only IL-12 but not IFN-αβ production reduced by endogenous DAP12 signaling in pDCs upon MCMV infection, when upon CpG challenge both types of cytokines were affected? DC responses to CpG stimulation are completely dependent on TLR-9 (42). During MCMV infection IL-12 production is strictly TLR-9 dependent, whereas other pathways significantly contribute

FIGURE 6. Increased frequencies of cytokine-producing pDCs in DAP12° mice upon MCMV infection or CpG challenge. Splenic leukocytes were isolated from day 1.5 (d1.5) MCMV-infected or 3-h CpG-injected WT or DAP12° mice and analyzed for intracellular IFN- $\alpha\beta$ and IL-12 within the pDC population. **A**, The frequency of IFN- $\alpha\beta$ ⁺ and IL-12⁺ pDCs is shown for one representative d1.5 MCMV-infected WT and one DAP12° animal from groups of three mice. Numbers in dot plots represent percentage of cytokine-positive pDCs. **B**, Frequency of cytokine-positive pDCs from d1.5 MCMV-infected WT and DAP12° mice from the experiment described in **A**. **C**, The frequency of IFN- $\alpha\beta$ ⁺ and IL-12⁺ pDCs is shown for mice injected with CpG as explained in **A**. **D**, Frequency of cytokine-positive pDCs from 3 h CpG-treated WT and DAP12° mice from the experiment described in **C**. Results of **B** and **D** are expressed as mean \pm SD of three mice per group. One experiment representative of three (for **A** and **B**) and two (for **C** and **D**) is shown. *, $p \leq 0.01$.



to pDC IFN- $\alpha\beta$ responses in vivo (32). Indeed, in addition to TLR-9 at least one other MyD88-dependent receptor promotes IFN- $\alpha\beta$ production by pDCs in vivo in response to MCMV infection, although its precise nature has not been elucidated. Potential candidates include TLR-7 or the IL1-R as discussed elsewhere (32). Thus, viral infection triggers IFN- $\alpha\beta$ production in pDCs via

multiple pathways, and the main part of the production is not affected by endogenous DAP12 signaling. In contrast, both virally induced and CpG-induced pDC IL-12 production result only from TLR-9 engagement and are down-modulated by DAP12. We thus show that MCMV infection overrides DAP12-mediated inhibition of IFN- $\alpha\beta$ but not IL-12 production in pDCs, and we speculate that this occurs either because the TLR-9-independent signals may be less sensitive to DAP12 inhibition or because the sum of the different activation pathways inducing IFN- $\alpha\beta$ generate a signal stronger than the one for IL-12 (Fig. 8). What could be the advantage, if any, of this differential regulation of IFN- $\alpha\beta$ vs IL-12 production by DAP12 in pDCs during viral infection? Systemic delivery of high levels of IFN- $\alpha\beta$ is observed during most viral but not other infections (43). It is critical for direct induction of protective antiviral defenses in potentially all of the tissue and cell types of the host (44) as well as for broad regulation of innate and adaptive immune responses (13). Lack of IFN- $\alpha\beta$ responses in humans and mice is lethal upon cytopathogenic viral infections (44, 45). In contrast, systemic IL-12 production is observed only during certain viral infections and is not believed to play direct antiviral effects (43). IL-12 acts on discrete subsets of immune cells to promote their activation, mostly IFN- γ production (43). Activation of NK cells by DCs for IFN- γ production requires formation of an immunological synapse with local release of IL-12 (46). Thus, systemic IL-12 responses may not be required for protective antiviral functions but lead to severe immunopathology when too high (14, 47). Therefore, during viral infection DAP12 functions may limit the production of IL-12 but allow secretion of high systemic levels of IFN- $\alpha\beta$ by pDCs to promote optimal antiviral defense by preserving strong, direct IFN- $\alpha\beta$ antiviral functions while dampening potentially dangerous inflammatory conditions (43). This outcome could be achieved because molecular pathways promoting IFN- $\alpha\beta$ production by pDCs in response to viral infection are multiple and, thus, stronger and more flexible than those for IL-12 production, and they are globally able to override DAP12-mediated inhibition. In this context, it is noteworthy that several mechanisms exist that cross-regulate IFN- $\alpha\beta$ and




FIGURE 7. Contrasting roles of endogenous DAP12 signaling in pDCs for the regulation of IL-12 and IFN- $\alpha\beta$ responses to CpG injection or MCMV infection. Frequency of cytokine-positive WT or DAP12° pDCs from 3-h CpG-treated or day 1.5 MCMV-infected mixed bone marrow chimeric mice generated as described in legend of Fig. 5. For each mouse, a pDC gate was set on PDCA-1⁺CD45.1⁺ cells, and another gate was set on PDCA-1⁺CD45.2⁺ cells. The frequency of cytokine-positive cells in each gate was then measured. Results are expressed as mean \pm SD of three mice per group for each pDC population. One experiment representative of two is shown. *, $p \leq 0.01$.




FIGURE 8. Hypothetical model for the differential regulation of pDC IL-12 and IFN- $\alpha\beta$ production by DAP12 during MCMV infection. CpG-induced pDC cytokine production results only from TLR-9 engagement and is down-modulated by DAP12 (A). In contrast, MCMV infection triggers IFN- $\alpha\beta$ production in pDCs via multiple TLR-9-dependent and -independent pathways that may lead to stronger signals than those in response to CpG, such that the main part of the production is not affected by endogenous DAP12 signaling. We thus propose that MCMV infection overrides DAP12-mediated inhibition of IFN- $\alpha\beta$ but not IL-12 production in pDCs, because the TLR-9-independent signals may be less sensitive to DAP12 inhibition (A). An alternative explanation could be that each of the different activation pathways inducing IFN- $\alpha\beta$ in response to MCMV can be subject to DAP12 inhibition, but the integration of their simultaneous triggering overcomes DAP12 inhibition (B). Potential candidate receptors for promotion of TLR-9-independent pDC IFN- $\alpha\beta$ production in response to MCMV infection include TLR-7, which is expressed in endosomal membranes, and the IL-1R, which is expressed at the plasma membrane.

proinflammatory cytokine production during infections or autoimmunity, such as the fact that IFN- $\alpha\beta$ production is enhanced through a positive feedback loop but inhibits IL-12 production, whereas TNF- α prevents pDC generation from hemopoietic progenitors and IFN- $\alpha\beta$ release from mature pDCs (10, 13).

One could further speculate that the cross-talk between pattern recognition receptors and DAP12-associated receptors expressed in pDCs promotes health over disease under noninfectious conditions as well as during viral challenges. Integration of activation signals delivered by various pattern recognition receptors and modulation signals delivered by DAP12-associated receptors could allow pDCs to sense their environment, measure the threat of viral infection, and balance the benefits of activation of antiviral defenses against the risk of development of immunopathology. This would be consistent with the recent observation that the simultaneous triggering of selected TLR pairs has strong synergistic

effects for cytokine production and induction of Th1 responses by DCs (48). In this context, it is interesting to note that low constitutive production of IFN- $\alpha\beta$ has been proposed to occur in the absence of overt viral infection, be critical for priming of antiviral responses upon productive infection, and require attenuation to avoid development of immunopathology (49). It would be interesting to determine whether pDCs contribute to the low spontaneous IFN- $\alpha\beta$ production and whether alterations in the cross-talk between TLRs and DAP12-associated receptors play a role in the enhanced pDC activation or increased IFN- $\alpha\beta$ levels observed in patients suffering from autoimmune diseases such as systemic lupus erythematosus, psoriasis, or insulin-dependent diabetes mellitus (1, 9–12, 50). Clarifying the pathways for pDC regulation in vivo could contribute to the development of new therapeutic strategies to modulate pDC functions for fighting viral infections or control autoimmune disease.

In summary, we identify here a crucial role of DAP12 in the regulation of pDC biology. DAP12 signaling has been demonstrated to exert indirect effects on pDC homeostasis, probably through the modulation of the functions of other cells, but also direct pDC-intrinsic effects on pDC cytokine production. We further show that endogenous DAP12 signaling in pDCs modulates both IFN- $\alpha\beta$ and IL-12 production upon CpG challenge in vivo, whereas it reduces only IL-12 but not IFN- $\alpha\beta$ production during viral infection. This finding led us to propose that the impact of DAP12 signaling on the regulation of IL-12 and IFN- $\alpha\beta$ production by pDCs depends on the physiopathological context and, more specifically, on the nature or the numbers of the pattern recognition receptors engaged for pDC activation.

Acknowledgments

We thank the staff from the animal care facilities and the flow cytometry core facility from the Centre d'Immunologie de Marseille-Luminy for excellent assistance, M.-B. Alter and M. Hagelin for excellent assistance in the animal facility at the Microbiology and Tumor Biology Center of the Karolinska Institute, A. Roume, Drs. V. Levitsky, B. Chambers, and C. Asselin-Paturel for help with the experiments, gift of reagents or helpful advice, and Dr. Takai for generous gift of the B6-DAP12.KO mice.

Disclosures

The authors have no financial conflict of interest.

References

- Liu, Y. J. 2005. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. *Annu. Rev. Immunol.* 23: 275–306.
- Honda, K., S. Sakaguchi, C. Nakajima, A. Watanabe, H. Yanai, M. Matsumoto, T. Ohteki, T. Kaisho, A. Takaoka, S. Akira, et al. 2003. Selective contribution of IFN- $\alpha\beta$ signaling to the maturation of dendritic cells induced by double-stranded RNA or viral infection. *Proc. Natl. Acad. Sci. USA* 100: 10872–10877.
- Dalod, M., T. Hamilton, R. Salomon, T. P. Salazar-Mather, S. C. Henry, J. D. Hamilton, and C. A. Biron. 2003. Dendritic cell responses to early murine cytomegalovirus infection: subset functional specialization and differential regulation by interferon $\alpha\beta$. *J. Exp. Med.* 197: 885–898.
- Asselin-Paturel, C., G. Brizard, K. Chemin, A. Boonstra, A. O'Garra, A. Vicari, and G. Trinchieri. 2005. Type I interferon dependence of plasmacytoid dendritic cell activation and migration. *J. Exp. Med.* 201: 1157–1167.
- Le Bon, A., N. Etchart, C. Rossmann, M. Ashton, S. Hou, D. Gewert, P. Borrow, and D. F. Tough. 2003. Cross-priming of CD8⁺ T cells stimulated by virus-induced type I interferon. *Nat. Immunol.* 4: 1009–1015.
- Hahn, B., M. J. Trifilo, E. I. Zuniga, and M. B. Oldstone. 2005. Viruses evade the immune system through type I interferon-mediated STAT2-dependent, but STAT1-independent, signaling. *Immunity* 22: 247–257.
- Mellor, A. L., B. Baban, P. R. Chandler, A. Manlapat, D. J. Kahler, and D. H. Munn. 2005. Cutting edge: CpG oligonucleotides induce splenic CD19⁺ dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN Type 1 signaling. *J. Immunol.* 175: 5601–5605.
- Le Bon, A., G. Schiavoni, G. D'Agostino, I. Gresser, F. Belardelli, and D. F. Tough. 2001. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. *Immunity* 14: 461–470.
- Nestle, F. O., C. Conrad, A. Tun-Kyi, B. Homey, M. Gombert, O. Boyman, G. Burg, Y. J. Liu, and M. Gilliet. 2005. Plasmacytoid dendritic cells initiate psoriasis through interferon- α production. *J. Exp. Med.* 202: 135–143.

10. Banchereau, J., V. Pascual, and A. K. Palucka. 2004. Autoimmunity through cytokine-induced dendritic cell activation. *Immunity* 20: 539–550.
11. Palucka, A. K., J. P. Blanck, L. Bennett, V. Pascual, and J. Banchereau. 2005. Cross-regulation of TNF and IFN- α in autoimmune diseases. *Proc. Natl. Acad. Sci. USA* 102: 3372–3377.
12. Theofilopoulos, A. N., R. Baccala, B. Beutler, and D. H. Kono. 2005. Type I interferons (α/β) in immunity and autoimmunity. *Annu. Rev. Immunol.* 23: 307–336.
13. Biron, C. A. 2001. Interferons α and β as immune regulators—a new look. *Immunity* 14: 661–664.
14. Gately, M. K., L. M. Renzetti, J. Magram, A. S. Stern, L. Adorini, U. Gubler, and D. H. Presky. 1998. The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. *Annu. Rev. Immunol.* 16: 495–521.
15. Martin, P., G. M. Del Hoyo, F. Anjuere, C. F. Arias, H. H. Vargas, L. A. Fernandez, V. Parrillas, and C. Ardavin. 2002. Characterization of a new subpopulation of mouse CD8 α^+ B220 $^+$ dendritic cells endowed with type I interferon production capacity and tolerogenic potential. *Blood* 100: 383–390.
16. Fallarino, F., C. Orabona, C. Vacca, R. Bianchi, S. Gizzi, C. Asselin-Paturel, M. C. Fioretti, G. Trinchieri, U. Grohmann, and P. Puccetti. 2005. Ligand and cytokine dependence of the immunosuppressive pathway of tryptophan catabolism in plasmacytoid dendritic cells. *Int. Immunol.* 17: 1429–1438.
17. Gilliet, M., and Y. J. Liu. 2002. Generation of human CD8 T regulatory cells by CD40 ligand-activated plasmacytoid dendritic cells. *J. Exp. Med.* 195: 695–704.
18. Moseman, E. A., X. Liang, A. J. Dawson, A. Panoskaltis-Mortari, A. M. Krieg, Y. J. Liu, B. R. Blazar, and W. Chen. 2004. Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4 $^+$ CD25 $^+$ regulatory T cells. *J. Immunol.* 173: 4433–4442.
19. de Heer, H. J., H. Hammad, T. Soullie, D. Hijdra, N. Vos, M. A. Willart, H. C. Hoogsteden, and B. N. Lambrecht. 2004. Essential role of lung plasmacytoid dendritic cells in preventing asthmatic reactions to harmless inhaled antigen. *J. Exp. Med.* 200: 89–98.
20. Dzionek, A., Y. Sohma, J. Nagafune, M. Cella, M. Colonna, F. Facchetti, G. Gunther, I. Johnston, A. Lanzavecchia, T. Nagasaka, et al. 2001. BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon α/β induction. *J. Exp. Med.* 194: 1823–1834.
21. Fuchs, A., M. Cella, T. Kondo, and M. Colonna. 2005. Paradoxical inhibition of human natural interferon-producing cells by the activating receptor NKp44. *Blood* 106: 2076–2082.
22. Blasius, A., W. Vermi, A. Krug, F. Facchetti, M. Cella, and M. Colonna. 2004. A cell surface molecule selectively expressed on murine natural interferon-producing cells that blocks secretion of interferon- α . *Blood* 103: 4201–4206.
23. Tomasello, E., and E. Vivier. 2005. KARAP/DAP12/TYROBP: three names and a multiplicity of biological functions. *Eur. J. Immunol.* 35: 1670–1677.
24. Orabona, C., P. Puccetti, C. Vacca, S. Bicchato, A. Luchini, F. Fallarino, R. Bianchi, E. Velardi, K. Perruccio, A. Velardi, et al. 2005. Towards the identification of a tolerogenic signature in IDO-competent dendritic cells. *Blood* 107: 2846–2854.
25. Orabona, C., E. Tomasello, F. Fallarino, R. Bianchi, C. Volpi, S. Bellocchio, L. Romani, M. C. Fioretti, E. Vivier, P. Puccetti, and U. Grohmann. 2005. Enhanced tryptophan catabolism in the absence of the molecular adapter DAP12. *Eur. J. Immunol.* 35: 3111–3118.
26. Bouchon, A., F. Facchetti, M. A. Weigand, and M. Colonna. 2001. TREM-1 amplifies inflammation and is a crucial mediator of septic shock. *Nature* 410: 1103–1107.
27. Turnbull, I. R., J. E. McDunn, T. Takai, R. R. Townsend, J. P. Cobb, and M. Colonna. 2005. DAP12 (KARAP) amplifies inflammation and increases mortality from endotoxemia and septic peritonitis. *J. Exp. Med.* 202: 363–369.
28. Hamerman, J. A., N. K. Tchao, C. A. Lowell, and L. L. Lanier. 2005. Enhanced Toll-like receptor responses in the absence of signaling adaptor DAP12. *Nat. Immunol.* 6: 579–586.
29. Blasius, A. L., M. Cella, J. Maldonado, T. Takai, and M. Colonna. 2006. Siglec-H is an IPC-specific receptor that modulates type I IFN secretion through DAP12. *Blood* 107: 2474–2476.
30. Krmpotic, A., I. Bubic, B. Polic, P. Lucin, and S. Jonjic. 2003. Pathogenesis of murine cytomegalovirus infection. *Microbes Infect.* 5: 1263–1277.
31. Dalod, M., T. P. Salazar-Mather, L. Malmgaard, C. Lewis, C. Asselin-Paturel, F. Briere, G. Trinchieri, and C. A. Biron. 2002. Interferon α/β and interleukin 12 responses to viral infections: pathways regulating dendritic cell cytokine expression in vivo. *J. Exp. Med.* 195: 517–528.
32. Delale, T., A. Paquin, C. Asselin-Paturel, M. Dalod, G. Brizard, E. E. Bates, P. Kastner, S. Chan, S. Akira, A. Vicari, et al. 2005. MyD88-dependent and -independent murine cytomegalovirus sensing for IFN- α release and initiation of immune responses in vivo. *J. Immunol.* 175: 6723–6732.
33. Krug, A., A. R. French, W. Barchet, J. A. Fischer, A. Dzionek, J. T. Pingel, M. M. Orihuela, S. Akira, W. M. Yokoyama, and M. Colonna. 2004. TLR9-dependent recognition of MCMV by IPC and DC generates coordinated cytokine responses that activate antiviral NK cell function. *Immunity* 21: 107–119.
34. Tabeta, K., P. Georgel, E. Janssen, X. Du, K. Hoebe, K. Crozat, S. Mudd, L. Shamel, S. Sovath, J. Goode, et al. 2004. Toll-like receptors 9 and 3 as essential components of innate immune defense against mouse cytomegalovirus infection. *Proc. Natl. Acad. Sci. USA* 101: 3516–3521.
35. Sjolín, H., E. Tomasello, M. Mousavi-Jazi, A. Bartolozzi, K. Karre, E. Vivier, and C. Cerboni. 2002. Pivotal role of KARAP/DAP12 adaptor molecule in the natural killer cell-mediated resistance to murine cytomegalovirus infection. *J. Exp. Med.* 195: 825–834.
36. Asselin-Paturel, C., G. Brizard, J. J. Pin, F. Briere, and G. Trinchieri. 2003. Mouse strain differences in plasmacytoid dendritic cell frequency and function revealed by a novel monoclonal antibody. *J. Immunol.* 171: 6466–6477.
37. Hidmark, A. S., G. M. McInerney, E. K. Nordstrom, I. Douagi, K. M. Werner, P. Liljestrom, and G. B. Karlsson Hedestam. 2005. Early α/β interferon production by myeloid dendritic cells in response to UV-inactivated virus requires viral entry and interferon regulatory factor 3 but not MyD88. *J. Virol.* 79: 10376–10385.
38. Gilliet, M., A. Boonstra, C. Paturel, S. Antonenko, X. L. Xu, G. Trinchieri, A. O'Garra, and Y. J. Liu. 2002. The development of murine plasmacytoid dendritic cell precursors is differentially regulated by FLT3-ligand and granulocyte/macrophage colony-stimulating factor. *J. Exp. Med.* 195: 953–958.
39. Tomasello, E., P. O. Desmoulin, K. Chemin, S. Guia, H. Cremer, J. Ortaldo, P. Love, D. Kaiserlian, and E. Vivier. 2000. Combined natural killer cell and dendritic cell functional deficiency in KARAP/DAP12 loss-of-function mutant mice. *Immunity* 13: 355–364.
40. Kaifu, T., J. Nakahara, M. Inui, K. Mishima, T. Momiyama, M. Kaji, A. Sugahara, H. Koito, A. Ujike-Asai, A. Nakamura, et al. 2003. Osteopetrosis and thalamic hypomyelination with synaptic degeneration in DAP12-deficient mice. *J. Clin. Invest.* 111: 323–332.
41. Hamerman, J. A., and L. L. Lanier. 2006. Inhibition of immune responses by ITAM-bearing receptors. *Sci. STKE* 2006: re1.
42. Hemmi, H., O. Takeuchi, T. Kawai, T. Kaisho, S. Sato, H. Sanjo, M. Matsumoto, K. Hoshino, H. Wagner, K. Takeda, and S. Akira. 2000. A Toll-like receptor recognizes bacterial DNA. *Nature* 408: 740–745.
43. Biron, C. A. 1999. Initial and innate responses to viral infections—pattern setting in immunity or disease. *Curr. Opin. Microbiol.* 2: 374–381.
44. Sen, G. C. 2001. Viruses and interferons. *Annu. Rev. Microbiol.* 55: 255–281.
45. Dupuis, S., E. Jouanguy, S. Al-Hajjar, C. Fieschi, I. Z. Al-Mohsen, S. Al-Jumaah, K. Yang, A. Chappier, C. Eidenschenk, P. Eid, et al. 2003. Impaired response to interferon- α/β and lethal viral disease in human STAT1 deficiency. *Nat. Genet.* 33: 388–391.
46. Borg, C., A. Jalil, D. Laderach, K. Maruyama, H. Wakasugi, S. Charrier, B. Ryffel, A. Cambi, C. Figdor, W. Vainchenker, et al. 2004. NK cell activation by dendritic cells (DCs) requires the formation of a synapse leading to IL-12 polarization in DCs. *Blood* 104: 3267–3275.
47. Fieschi, C., S. Dupuis, E. Catherinot, J. Feinberg, J. Bustamante, A. Breiman, F. Altare, R. Baretto, F. Le Deist, S. Kayal, et al. 2003. Low penetrance, broad resistance, and favorable outcome of interleukin 12 receptor β 1 deficiency: medical and immunological implications. *J. Exp. Med.* 197: 527–535.
48. Napolitani, G., A. Rinaldi, F. Bertoni, F. Sallusto, and A. Lanzavecchia. 2005. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. *Nat. Immunol.* 6: 769–776.
49. Taniguchi, T., and A. Takaoka. 2001. A weak signal for strong responses: interferon- α/β revisited. *Nat. Rev. Mol. Cell Biol.* 2: 378–386.
50. Toyabe, S., U. Kaneko, and M. Uchiyama. 2004. Decreased DAP12 expression in natural killer lymphocytes from patients with systemic lupus erythematosus is associated with increased transcript mutations. *J. Autoimmun.* 23: 371–378.